Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Acquisitions (2017 - 2019)

IGC Pharma (IGC) has disclosed Acquisitions for 8 consecutive years, with $19000.0 as the latest value for Q3 2019.

  • On a quarterly basis, Acquisitions rose 137.5% to $19000.0 in Q3 2019 year-over-year; TTM through Sep 2019 was $55000.0, a 193.22% increase, with the full-year FY2019 number at $45000.0, down 30.77% from a year prior.
  • Acquisitions was $19000.0 for Q3 2019 at IGC Pharma, up from $4000.0 in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $149000.0 in Q4 2017 to a low of -$221000.0 in Q1 2018.
  • A 5-year average of $146.17 and a median of $4500.0 in 2018 define the central range for Acquisitions.
  • Peak YoY movement for Acquisitions: plummeted 3862.56% in 2016, then soared 137.5% in 2019.
  • IGC Pharma's Acquisitions stood at -$414.0 in 2015, then tumbled by 3862.56% to -$16405.0 in 2016, then soared by 1008.26% to $149000.0 in 2017, then tumbled by 80.54% to $29000.0 in 2018, then tumbled by 34.48% to $19000.0 in 2019.
  • Per Business Quant, the three most recent readings for IGC's Acquisitions are $19000.0 (Q3 2019), $4000.0 (Q2 2019), and $3000.0 (Q1 2019).